{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:18:28Z","timestamp":1794557908786,"version":"4.9.1"},"reference-count":118,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,23]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The epidemiology of invasive fungal infections (IFIs) among patients receiving Bruton tyrosine kinase inhibitors (BTKIs) remains incompletely characterized. We conducted a systematic review and meta-analysis of 88 studies including 23\u2009737 patients to evaluate the prevalence and risk factors for IFIs in this population. Among 16 studies that applied the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium consensus definitions of IFIs, the pooled prevalence of proven\/probable IFIs was 2.83% (95% confidence interval [CI], 1.97-4.06), with the highest prevalence observed in patients with central nervous system lymphoma (9.02%). Aspergillosis was the most frequently reported IFI (1.76%), followed by pneumocystosis, candidiasis, and cryptococcosis. The risk factors significantly associated with proven\/probable IFIs were concurrent corticosteroid use (odds ratio [OR], 5.03; 95% CI, 2.31-10.92) and \u22653 previous lines of therapy (OR, 3.26; 95% CI, 1.54-6.88). Across clinical trials, the prevalence of fungal infections varied across BTKI agents, ranging from 2.50% with tirabrutinib, to 0.62% with pirtobrutinib. Data on antifungal and Pneumocystis jirovecii pneumonia prophylaxis were limited and inconclusive. Among clinical trials that reported fungal infections as adverse events, the prevalence of IFI was the highest in patients treated with tirabrutinib (2.50%), followed by zanubrutinib (2.13%), ibrutinib (1.75%), acalabrutinib (1.31%), orelabrutinib (1.08%), and pirtobrutinib (0.62%). Although some findings suggest a potential benefit in selected patients, current evidence remains insufficient to support broad prophylaxis recommendations. These results underscore the need for individualized risk assessment and further research to inform prevention strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025019221","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T14:55:59Z","timestamp":1775746559000},"page":"4171-4182","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["Invasive fungal infections after Bruton tyrosine kinase inhibitor treatment: a systematic review and meta-analysis"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9296-6344","authenticated-orcid":false,"given":"Karan","family":"Srisurapanont","sequence":"first","affiliation":[{"name":"1Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9544-7096","authenticated-orcid":false,"given":"Tanaporn","family":"Meejun","sequence":"additional","affiliation":[{"name":"2Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2446-143X","authenticated-orcid":false,"given":"Kasama","family":"Manothummetha","sequence":"additional","affiliation":[{"name":"3Department of Medicine, University of Miami, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5857-6227","authenticated-orcid":false,"given":"Lucy X.","family":"Li","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9111-625X","authenticated-orcid":false,"given":"John W.","family":"Baddley","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cory A.","family":"Schulz","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5326-9551","authenticated-orcid":false,"given":"M. Veronica","family":"Dioverti-Prono","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1166-2563","authenticated-orcid":false,"given":"Sean X.","family":"Zhang","sequence":"additional","affiliation":[{"name":"4Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7692-3619","authenticated-orcid":false,"given":"Robin K.","family":"Avery","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4381-0049","authenticated-orcid":false,"given":"Olivia S.","family":"Kates","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0749-7342","authenticated-orcid":false,"given":"Nitipong","family":"Permpalung","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD"},{"name":"2Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"issue":"1","key":"2026062308470666000_bib1","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1182\/hematology.2020000118","article-title":"Managing toxicities of Bruton tyrosine kinase inhibitors","volume":"2020","author":"Lipsky","year":"2020","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"6","key":"2026062308470666000_bib2","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"18","key":"2026062308470666000_bib3","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1182\/blood-2017-12-823393","article-title":"Ibrutinib blocks Btk-dependent NF-\u0138B and NFAT responses in human macrophages during Aspergillus fumigatus phagocytosis","volume":"132","author":"Bercusson","year":"2018","journal-title":"Blood"},{"issue":"6","key":"2026062308470666000_bib4","doi-asserted-by":"crossref","first-page":"e1003446","DOI":"10.1371\/journal.ppat.1003446","article-title":"Bruton\u2019s tyrosine kinase (BTK) and Vav1 contribute to Dectin1-dependent phagocytosis of Candida albicans in macrophages","volume":"9","author":"Strijbis","year":"2013","journal-title":"Plos Pathog"},{"issue":"2","key":"2026062308470666000_bib5","doi-asserted-by":"crossref","first-page":"478","DOI":"10.3324\/haematol.2019.219220","article-title":"Ibrutinib induces multiple functional defects in the neutrophil response against Aspergillus fumigatus","volume":"105","author":"Blez","year":"2020","journal-title":"Haematologica"},{"key":"2026062308470666000_bib6","doi-asserted-by":"crossref","first-page":"107000","DOI":"10.1016\/j.ijid.2024.107000","article-title":"Invasive Aspergillosis with impaired neutrophil responses against Aspergillus fumigatus in patients treated with acalabrutinib-findings from three cases","volume":"142","author":"Blaize","year":"2024","journal-title":"Int J Infect Dis"},{"issue":"7","key":"2026062308470666000_bib7","doi-asserted-by":"crossref","first-page":"E174","DOI":"10.1002\/ajh.25816","article-title":"Second generation BTK inhibitors impair the anti-fungal response of macrophages and neutrophils","volume":"95","author":"Colado","year":"2020","journal-title":"Am J Hematol"},{"issue":"8","key":"2026062308470666000_bib8","doi-asserted-by":"crossref","first-page":"e0004223","DOI":"10.1128\/iai.00042-23","article-title":"Susceptibility to Cryptococcus neoformans infection with Bruton\u2019s tyrosine kinase inhibition","volume":"91","author":"Messina","year":"2023","journal-title":"Infect Immun"},{"issue":"5","key":"2026062308470666000_bib9","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1007\/s12185-009-0322-5","article-title":"Pneumocystis jiroveci pneumonia as an atypical presentation of X-linked agammaglobulinemia","volume":"89","author":"Kanegane","year":"2009","journal-title":"Int J Hematol"},{"issue":"1","key":"2026062308470666000_bib10","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.anai.2013.10.008","article-title":"X-linked agammaglobulinemia presenting as polymicrobial pneumonia, including Pneumocystis jirovecii","volume":"112","author":"Jongco","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"9","key":"2026062308470666000_bib11","doi-asserted-by":"crossref","first-page":"E966","DOI":"10.1073\/pnas.1500712112","article-title":"Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK","volume":"112","author":"Sagiv-Barfi","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2026062308470666000_bib12","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"issue":"2","key":"2026062308470666000_bib13","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1470-2045(16)30632-5","article-title":"Ibrutinib for patients with rituximab-refractory Waldenstr\u00f6m\u2019s macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol"},{"issue":"6","key":"2026062308470666000_bib14","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.ccell.2017.04.012","article-title":"Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma","volume":"31","author":"Lionakis","year":"2017","journal-title":"Cancer Cell"},{"issue":"17","key":"2026062308470666000_bib15","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1182\/blood-2017-11-818286","article-title":"Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib","volume":"131","author":"Ghez","year":"2018","journal-title":"Blood"},{"issue":"12","key":"2026062308470666000_bib16","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1111\/myc.13001","article-title":"Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: an observational study","volume":"62","author":"Ruchlemer","year":"2019","journal-title":"Mycoses"},{"issue":"11","key":"2026062308470666000_bib17","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1038\/s41375-021-01252-y","article-title":"Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies","volume":"35","author":"Furman","year":"2021","journal-title":"Leukemia"},{"issue":"4","key":"2026062308470666000_bib18","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1182\/bloodadvances.2021005621","article-title":"Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies","volume":"6","author":"Tam","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"2026062308470666000_bib19","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/neuonc\/noaa145","article-title":"Phase I\/II study of tirabrutinib, a second-generation Bruton\u2019s tyrosine kinase inhibitor, in relapsed\/refractory primary central nervous system lymphoma","volume":"23","author":"Narita","year":"2021","journal-title":"Neuro Oncol"},{"issue":"16","key":"2026062308470666000_bib20","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1182\/bloodadvances.2022009168","article-title":"Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1\/2, open-label, multicenter, single-arm study","volume":"7","author":"Deng","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"2026062308470666000_bib21","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2300696","article-title":"Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia","volume":"389","author":"Mato","year":"2023","journal-title":"N Engl J Med"},{"issue":"5","key":"2026062308470666000_bib22","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.cmi.2024.12.032","article-title":"Fungal infection in patients treated with Bruton tyrosine kinase inhibitor-from epidemiology to clinical outcome: a systematic review","volume":"31","author":"Gibert","year":"2025","journal-title":"Clin Microbiol Infect"},{"key":"2026062308470666000_bib23","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"12","key":"2026062308470666000_bib24","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2026062308470666000_bib25","unstructured":"CTEP Trial Development and Conduct. NCI. Updated 25 June 2025. Accessed 15 July 2025. https:\/\/dctd.cancer.gov\/research\/ctep-trials\/trial-development."},{"issue":"9","key":"2026062308470666000_bib26","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jclinepi.2011.11.014","article-title":"Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement","volume":"65","author":"Hoy","year":"2012","journal-title":"J Clin Epidemiol"},{"key":"2026062308470666000_bib27","author":"Wells","year":"2011"},{"issue":"7650","key":"2026062308470666000_bib28","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"2026062308470666000_bib29","author":"World Health Organization","year":"2024"},{"issue":"4","key":"2026062308470666000_bib30","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/XEB.0000000000000141","article-title":"A new improved graphical and quantitative method for detecting bias in meta-analysis","volume":"16","author":"Furuya-Kanamori","year":"2018","journal-title":"Int J Evid Based Healthc"},{"issue":"4","key":"2026062308470666000_bib31","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/bjh.15627","article-title":"Low risk of Pneumocystis jirovecii pneumonia and invasive aspergillosis in patients with Waldenstr\u00f6m macroglobulinaemia on ibrutinib","volume":"185","author":"Cheng","year":"2019","journal-title":"Br J Haematol"},{"issue":"4","key":"2026062308470666000_bib32","doi-asserted-by":"crossref","first-page":"438","DOI":"10.21320\/2500-2139-2019-12-4-438-448","article-title":"Infections in Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib: Incidence and Predisposing Factors","volume":"12","author":"Dmitrieva","year":"2019","journal-title":"Clinical Oncohematology"},{"issue":"9","key":"2026062308470666000_bib33","doi-asserted-by":"crossref","first-page":"myac061","DOI":"10.1093\/mmy\/myac061","article-title":"Incidence of invasive fungal infections in patients with hematological malignancies receiving ibrutinib therapy in south-east Austria","volume":"60","author":"Egger","year":"2022","journal-title":"Med Mycol"},{"issue":"10","key":"2026062308470666000_bib34","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1080\/10428194.2020.1775215","article-title":"Incidence and characterization of fungal infections in chronic lymphocytic leukemia patients receiving ibrutinib","volume":"61","author":"Frei","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"2026062308470666000_bib35","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.jiac.2021.08.005","article-title":"Incidence and associated risk factors for invasive fungal infections and other serious infections in patients on ibrutinib","volume":"27","author":"Holowka","year":"2021","journal-title":"J Infect Chemother"},{"issue":"4","key":"2026062308470666000_bib36","first-page":"191","article-title":"Clinical outcomes of CNS lymphoma treated with ibrutinib-based therapy: a real-life multicenter experience on off-label use of ibrutinib","volume":"33","author":"Iltar","year":"2023","journal-title":"UHOD"},{"issue":"21","key":"2026062308470666000_bib37","doi-asserted-by":"crossref","first-page":"7629","DOI":"10.1002\/cam4.4293","article-title":"Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: a multicentric real-world study","volume":"10","author":"Stefania Infante","year":"2021","journal-title":"Cancer Med"},{"issue":"6","key":"2026062308470666000_bib38","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1111\/bjh.16946","article-title":"Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance\/MD Anderson Cancer Center experience","volume":"192","author":"Lewis","year":"2021","journal-title":"Br J Haematol"},{"issue":"2","key":"2026062308470666000_bib39","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/bjh.17145","article-title":"Infections in patients with lymphoproliferative diseases treated with targeted agents: SEIFEM multicentric retrospective study","volume":"193","author":"Marchesini","year":"2021","journal-title":"Br J Haematol"},{"issue":"10","key":"2026062308470666000_bib40","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1038\/s41375-019-0481-1","article-title":"Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies","volume":"33","author":"Rogers","year":"2019","journal-title":"Leukemia"},{"issue":"6","key":"2026062308470666000_bib41","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1080\/10428194.2018.1543884","article-title":"High rates of proven invasive fungal disease with the use of ibrutinib monotherapy for relapsed or refractory chronic lymphocytic leukemia","volume":"60","author":"Teh","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2026062308470666000_bib42","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/ajhp\/zxad210","article-title":"Infectious complications among patients receiving ibrutinib for the treatment of hematological malignancies","volume":"81","author":"Tham","year":"2024","journal-title":"Am J Health Syst Pharm"},{"issue":"5","key":"2026062308470666000_bib43","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/cid\/ciy175","article-title":"Serious infections in patients receiving ibrutinib for treatment of lymphoid cancer","volume":"67","author":"Varughese","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"4","key":"2026062308470666000_bib44","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1177\/10781552231181113","article-title":"Incidence of invasive fungal infections in patients with chronic lymphocytic leukemia receiving ibrutinib within the veteran\u2019s healthcare administration","volume":"30","author":"Walker","year":"2024","journal-title":"J Oncol Pharm Pract"},{"issue":"12","key":"2026062308470666000_bib45","doi-asserted-by":"crossref","first-page":"e985","DOI":"10.1016\/j.clml.2021.07.022","article-title":"Real-world characteristics and outcome of patients treated with single-agent ibrutinib for chronic lymphocytic leukemia in Spain (IBRORS-LLC Study)","volume":"21","author":"Abrisqueta","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"15","key":"2026062308470666000_bib46","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1182\/blood-2016-06-722991","article-title":"Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib","volume":"128","author":"Ahn","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2026062308470666000_bib47","doi-asserted-by":"crossref","first-page":"e13676","DOI":"10.1111\/myc.13676","article-title":"Invasive fungal infection incidence and risk factors in patients receiving ibrutinib in real-life settings: a nationwide population-based cohort study","volume":"67","author":"Allouchery","year":"2024","journal-title":"Mycoses"},{"issue":"3","key":"2026062308470666000_bib48","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1080\/10428194.2022.2157676","article-title":"Australian experience with ibrutinib in patients with relapsed\/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry","volume":"64","author":"Baggio","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"2026062308470666000_bib49","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1080\/10428194.2017.1320710","article-title":"Fungal infections in patients treated with ibrutinib: two unusual cases of invasive aspergillosis and cryptococcal meningoencephalitis","volume":"58","author":"Baron","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"2026062308470666000_bib50","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1080\/10428194.2022.2056179","article-title":"Incidence of Pneumocystis jirovecii pneumonia (PJP) in patients receiving BTK inhibitors who did not receive PJP prophylaxis","volume":"63","author":"Davis","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"2026062308470666000_bib51","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1080\/10428194.2019.1620944","article-title":"Safety and efficacy analysis of long-term follow up real-world data with ibrutinib monotherapy in 58 patients with CLL treated in a single-center in Greece","volume":"60","author":"Dimou","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2026062308470666000_bib52","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/cid\/ciab1026","article-title":"Incidence of invasive fungal infections in patients initiating ibrutinib and other small molecule kinase inhibitors-United States, July 2016-June 2019","volume":"75","author":"Gold","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"13","key":"2026062308470666000_bib53","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.3390\/cancers13133240","article-title":"Prognostic impact and risk factors of infections in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"13","author":"Mauro","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2026062308470666000_bib54","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s12185-024-03875-0","article-title":"Real-world effectiveness and safety of ibrutinib in patients with chronic lymphocytic leukemia in Japan: the Orbit study","volume":"121","author":"Muta","year":"2025","journal-title":"Int J Hematol"},{"issue":"5","key":"2026062308470666000_bib55","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1182\/bloodadvances.2024014374","article-title":"Ibrutinib for therapy of steroid-refractory chronic graft-versus-host disease: a multicenter real-world analysis","volume":"9","author":"Pidala","year":"2025","journal-title":"Blood Adv"},{"issue":"7","key":"2026062308470666000_bib56","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/bloodadvances.2020001678","article-title":"Pneumocystis jirovecii pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitors","volume":"4","author":"Ryan","year":"2020","journal-title":"Blood Adv"},{"issue":"5","key":"2026062308470666000_bib57","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/ejh.13928","article-title":"High risk of infection in \u2018real-world\u2019 patients receiving ibrutinib, idelalisib or venetoclax for mature B-cell leukaemia\/lymphoma","volume":"110","author":"Tey","year":"2023","journal-title":"Eur J Haematol"},{"issue":"3","key":"2026062308470666000_bib58","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1080\/10428194.2022.2161305","article-title":"Oral azole antifungal prophylaxis in Japanese patients with chronic lymphocytic leukemia receiving ibrutinib: a nationwide cohort study","volume":"64","author":"Yasu","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2026062308470666000_bib59","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1182\/bloodadvances.2023011574","article-title":"Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL","volume":"8","author":"Ahn","year":"2024","journal-title":"Blood Adv"},{"issue":"20","key":"2026062308470666000_bib60","doi-asserted-by":"crossref","first-page":"5492","DOI":"10.1158\/1078-0432.CCR-21-0539","article-title":"A phase II trial of the Bruton tyrosine-kinase inhibitor zanubrutinib (BGB-3111) in patients with relapsed\/refractory Waldenstr\u00f6m macroglobulinemia","volume":"27","author":"An","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2026062308470666000_bib61","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N Engl J Med"},{"issue":"8","key":"2026062308470666000_bib62","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1056\/NEJMoa2409804","article-title":"Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia","volume":"392","author":"Brown","year":"2025","journal-title":"N Engl J Med"},{"issue":"3","key":"2026062308470666000_bib63","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"issue":"15","key":"2026062308470666000_bib64","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1182\/blood.2018884940","article-title":"Acalabrutinib monotherapy in patients with relapsed\/refractory chronic lymphocytic leukemia: updated phase 2 results","volume":"135","author":"Byrd","year":"2020","journal-title":"Blood"},{"issue":"11","key":"2026062308470666000_bib65","first-page":"771.e1","article-title":"Ibrutinib treatment of pediatric chronic graft-versus-host disease: primary results from the phase 1\/2 iMAGINE study","volume":"28","author":"Carpenter","year":"2022","journal-title":"Transpl Cell Ther"},{"issue":"4","key":"2026062308470666000_bib66","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1182\/blood.2024023847","article-title":"Ibrutinib as part of risk-stratified treatment for posttransplant lymphoproliferative disorder: the phase 2 TIDaL trial","volume":"144","author":"Chaganti","year":"2024","journal-title":"Blood"},{"issue":"5","key":"2026062308470666000_bib67","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1111\/bjh.17994","article-title":"Zanubrutinib for treatment-na\u00efve and relapsed\/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I\/II AU-003 study","volume":"196","author":"Cull","year":"2022","journal-title":"Br J Haematol"},{"issue":"1","key":"2026062308470666000_bib68","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/S2352-3026(18)30196-0","article-title":"Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study","volume":"6","author":"Davids","year":"2019","journal-title":"Lancet Haematol"},{"issue":"13","key":"2026062308470666000_bib69","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1080\/10428194.2020.1795159","article-title":"Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"61","author":"Fraser","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2026062308470666000_bib70","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S1470-2045(24)00196-7","article-title":"First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA\/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial","volume":"25","author":"F\u00fcrstenau","year":"2024","journal-title":"Lancet Oncol"},{"issue":"12","key":"2026062308470666000_bib71","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1182\/blood.2024026685","article-title":"MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial","volume":"145","author":"F\u00fcrstenau","year":"2025","journal-title":"Blood"},{"issue":"12","key":"2026062308470666000_bib72","doi-asserted-by":"crossref","first-page":"e801","DOI":"10.1097\/HS9.0000000000000801","article-title":"Acalabrutinib versus investigator\u2019s choice in relapsed\/refractory chronic lymphocytic leukemia: final ASCEND trial results","volume":"6","author":"Ghia","year":"2022","journal-title":"Hemasphere"},{"issue":"18","key":"2026062308470666000_bib73","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1158\/1078-0432.CCR-24-0605","article-title":"A phase II study assessing long-term response to ibrutinib monotherapy in recurrent or refractory CNS lymphoma","volume":"30","author":"Grommes","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"30","key":"2026062308470666000_bib74","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1200\/JCO.19.00894","article-title":"Ibrutinib plus venetoclax in relapsed\/refractory chronic lymphocytic leukemia: the CLARITY study","volume":"37","author":"Hillmen","year":"2019","journal-title":"J Clin Oncol"},{"issue":"5","key":"2026062308470666000_bib75","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1470-2045(23)00144-4","article-title":"Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Hillmen","year":"2023","journal-title":"Lancet Oncol"},{"issue":"9","key":"2026062308470666000_bib76","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1182\/blood.2021013208","article-title":"Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia","volume":"139","author":"Huber","year":"2022","journal-title":"Blood"},{"issue":"2","key":"2026062308470666000_bib77","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.21.01797","article-title":"Ibrutinib with rituximab in first-line treatment of older patients with mantle cell lymphoma","volume":"40","author":"Jain","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026062308470666000_bib78","doi-asserted-by":"crossref","first-page":"e692","DOI":"10.1097\/HS9.0000000000000692","article-title":"Efficacy and safety of the combination of tirabrutinib and entospletinib with or without obinutuzumab in relapsed chronic lymphocytic leukemia","volume":"6","author":"Kutsch","year":"2022","journal-title":"Hemasphere"},{"issue":"1","key":"2026062308470666000_bib79","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3390\/cancers14010207","article-title":"Efficacy of front-line ibrutinib and rituximab combination and the impact of treatment discontinuation in unfit patients with chronic lymphocytic leukemia: results of the Gimema LLC1114 Study","volume":"14","author":"Mauro","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"15","key":"2026062308470666000_bib80","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1182\/bloodadvances.2022009594","article-title":"A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial","volume":"7","author":"Michallet","year":"2023","journal-title":"Blood Adv"},{"issue":"22","key":"2026062308470666000_bib81","doi-asserted-by":"crossref","first-page":"7141","DOI":"10.1182\/bloodadvances.2023010298","article-title":"Phase 3 SELENE study: ibrutinib plus BR\/R-CHOP in previously treated patients with follicular or marginal zone lymphoma","volume":"7","author":"Nastoupil","year":"2023","journal-title":"Blood Adv"},{"issue":"10","key":"2026062308470666000_bib82","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1470-2045(16)30212-1","article-title":"Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study","volume":"17","author":"O\u2019Brien","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"2026062308470666000_bib83","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1016\/S2352-3026(19)30210-8","article-title":"Acalabrutinib monotherapy in patients with Waldenstr\u00f6m macroglobulinemia: a single-arm, multicentre, phase 2 study","volume":"7","author":"Owen","year":"2020","journal-title":"Lancet Haematol"},{"issue":"1","key":"2026062308470666000_bib84","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1038\/s41467-024-47198-4","article-title":"Combination of acalabrutinib with lenalidomide and rituximab in relapsed\/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial","volume":"15","author":"Park","year":"2024","journal-title":"Nat Commun"},{"issue":"17","key":"2026062308470666000_bib85","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1158\/1078-0432.CCR-24-0183","article-title":"Ibrutinib in combination with R-GemOx in patients with relapsed or refractory diffuse large B-cell lymphoma of nongerminal center B-cell-like type: phase II clinical trial of the Spanish GELTAMO Group","volume":"30","author":"Rey-B\u00faa","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"25","key":"2026062308470666000_bib86","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1182\/blood.2020009688","article-title":"Phase 2 study of ibrutinib in classic and variant hairy cell leukemia","volume":"137","author":"Rogers","year":"2021","journal-title":"Blood"},{"issue":"9","key":"2026062308470666000_bib87","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.3324\/haematol.2020.272500","article-title":"Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"106","author":"Rogers","year":"2021","journal-title":"Haematologica"},{"issue":"4","key":"2026062308470666000_bib88","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/s41375-023-01830-2","article-title":"A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia","volume":"37","author":"Ryan","year":"2023","journal-title":"Leukemia"},{"issue":"8","key":"2026062308470666000_bib89","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood.2022018818","article-title":"Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial","volume":"142","author":"Seymour","year":"2023","journal-title":"Blood"},{"issue":"21","key":"2026062308470666000_bib90","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1200\/JCO-25-00758","article-title":"Zanubrutinib and venetoclax for patients with treatment-na\u00efve chronic lymphocytic leukemia\/small lymphocytic lymphoma with and without Del(17p)\/TP53 mutation: SEQUOIA Arm D results","volume":"43","author":"Shadman","year":"2025","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026062308470666000_bib91","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S2352-3026(20)30433-6","article-title":"Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial","volume":"8","author":"Sharman","year":"2021","journal-title":"Lancet Haematol"},{"issue":"10232","key":"2026062308470666000_bib92","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"2026062308470666000_bib93","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s12288-020-01378-6","article-title":"Efficacy, safety, and quality of life of generic and innovator ibrutinib in Indian CLL patients","volume":"37","author":"Singh","year":"2021","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"21","key":"2026062308470666000_bib94","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood.2021014162","article-title":"Zanubrutinib in relapsed\/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study","volume":"139","author":"Song","year":"2022","journal-title":"Blood"},{"key":"2026062308470666000_bib95","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejca.2019.05.024","article-title":"Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II \u2018proof-of-concept\u2019 iLOC study by the Lymphoma Study Association (LYSA) and the French oculo-cerebral lymphoma (LOC) network","volume":"117","author":"Soussain","year":"2019","journal-title":"Eur J Cancer"},{"issue":"1","key":"2026062308470666000_bib96","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1182\/blood.2019003715","article-title":"Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib","volume":"136","author":"Sun","year":"2020","journal-title":"Blood"},{"issue":"18","key":"2026062308470666000_bib97","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.2020006844","article-title":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: the ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"issue":"19","key":"2026062308470666000_bib98","doi-asserted-by":"crossref","first-page":"4802","DOI":"10.1182\/bloodadvances.2020002183","article-title":"Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma","volume":"4","author":"Tam","year":"2020","journal-title":"Blood Adv"},{"issue":"12","key":"2026062308470666000_bib99","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1182\/bloodadvances.2020004074","article-title":"Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma","volume":"5","author":"Tam","year":"2021","journal-title":"Blood Adv"},{"issue":"8","key":"2026062308470666000_bib100","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","article-title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","volume":"23","author":"Tam","year":"2022","journal-title":"Lancet Oncol"},{"issue":"18","key":"2026062308470666000_bib101","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1182\/blood.2020006449","article-title":"Zanubrutinib for the treatment of patients with Waldenstr\u00f6m macroglobulinemia: 3 years of follow-up","volume":"136","author":"Trotman","year":"2020","journal-title":"Blood"},{"issue":"11","key":"2026062308470666000_bib102","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1182\/bloodadvances.2022009382","article-title":"Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemia","volume":"7","author":"Wallace","year":"2023","journal-title":"Blood Adv"},{"issue":"10","key":"2026062308470666000_bib103","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1016\/j.bbmt.2019.06.023","article-title":"Ibrutinib for chronic graft-versus-host disease after failure of prior therapy: 1-year update of a phase 1b\/2 study","volume":"25","author":"Waller","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"26","key":"2026062308470666000_bib104","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa2201817","article-title":"Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma","volume":"386","author":"Wang","year":"2022","journal-title":"N Engl J Med"},{"issue":"24","key":"2026062308470666000_bib105","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1200\/JCO.23.00562","article-title":"Pirtobrutinib in covalent Bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026062308470666000_bib106","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1470-2045(24)00682-X","article-title":"Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"26","author":"Wang","year":"2025","journal-title":"Lancet Oncol"},{"issue":"10121","key":"2026062308470666000_bib107","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"2026062308470666000_bib108","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1200\/JCO.22.00597","article-title":"Smart start: rituximab, lenalidomide, and ibrutinib in patients with newly diagnosed large B-cell lymphoma","volume":"41","author":"Westin","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026062308470666000_bib109","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/ajh.26826","article-title":"Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma patients: multi-center, single-arm, open-label, phase 2 study","volume":"98","author":"Xu","year":"2023","journal-title":"Am J Hematol"},{"issue":"1","key":"2026062308470666000_bib110","first-page":"vdae037","article-title":"Three-year follow-up analysis of phase 1\/2 study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma","volume":"6","author":"Yonezawa","year":"2024","journal-title":"Neurooncol Adv"},{"issue":"15","key":"2026062308470666000_bib111","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.18.02403","article-title":"Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma","volume":"37","author":"Younes","year":"2019","journal-title":"J Clin Oncol"},{"issue":"33","key":"2026062308470666000_bib112","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1200\/JCO.23.00775","article-title":"ROSEWOOD: a phase II randomized study of zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma","volume":"41","author":"Zinzani","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10277","key":"2026062308470666000_bib113","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0140-6736(21)00235-X","article-title":"Pirtobrutinib shows evidence to inaugurate a third generation of BTK inhibitors","volume":"397","author":"Michot","year":"2021","journal-title":"Lancet"},{"issue":"7","key":"2026062308470666000_bib114","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1038\/s41375-025-02586-7","article-title":"Primary antifungal prophylaxis in hematological malignancies. Updated clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL)","volume":"39","author":"Pagano","year":"2025","journal-title":"Leukemia"},{"issue":"5","key":"2026062308470666000_bib115","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/annrheumdis-2017-212588","article-title":"Pneumocystis and glucocorticoid use: to prophylax or not to prophylax (and when?); that is the question","volume":"77","author":"Winthrop","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"2026062308470666000_bib116","doi-asserted-by":"crossref","first-page":"ofae115","DOI":"10.1093\/ofid\/ofae115","article-title":"Risk of invasive fungal infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors: a case-control propensity score-matched analysis","volume":"11","author":"Agudelo Higuita","year":"2024","journal-title":"Open Forum Infect Dis"},{"issue":"suppl 2","key":"2026062308470666000_bib117","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/j.cmi.2018.02.009","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (intracellular signaling pathways: tyrosine kinase and mTOR inhibitors)","volume":"24","author":"Reinwald","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2026062308470666000_bib118","author":"Baden","year":"2025"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/12\/4171\/2526578\/blooda_adv-2025-019221-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/12\/4171\/2526578\/blooda_adv-2025-019221-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T12:49:21Z","timestamp":1782218961000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/12\/4171\/567644\/Invasive-fungal-infections-after-Bruton-tyrosine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":118,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,6,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025019221","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6,23]]},"published":{"date-parts":[[2026,6,10]]}}}